Nexalin Technology (NXL) Net Equity Issued and Repurchased (2021 - 2026)
Nexalin Technology (NXL) posted quarterly Net Equity Issued and Repurchased of $756000.0 for Q1 2026, down 91.15% quarter-over-quarter from $8.5 million in Q3 2022.
Nexalin Technology (NXL) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Nexalin Technology's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $756000.0 for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $756000.0; the TTM figure through Mar 2026 stood at $756000.0 (changed N/A YoY), while the FY2025 annual figure was $4.6 million, up 2.88% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $756000.0, down from $8.5 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $8.5 million in Q3 2022, with the low at $5100.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | - |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | Nexalin Technology | 7.04 Mn | 6.03 Mn | 8,897.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 756,000.00 |
| Mar 31, 2026 | 756,000.00 |
| Sep 30, 2022 | 8.54 Mn |
| Sep 30, 2022 | 8.54 Mn |
| Mar 31, 2022 | 5,100.00 |
| Mar 31, 2022 | 5,100.00 |
| Dec 31, 2021 | 762,360.00 |
| Dec 31, 2021 | 762,360.00 |